Fig. 3.

ErbB3-binding ABD molecules disrupt binding of NRG-β1 to ErbB3. 5 nM hErbB3 was incubated with indicated concentrations of binder and injected over immobilized NRG-β1 ECD (entire extracellular domain). Obtained max responses were normalized against a corresponding injection with untreated hErbB3. Bars represent mean values with indicated standard deviations from two injections over three surfaces (n = 6). Control injection NRG-β1 EGF (receptor-binding part) was performed only once (n = 3). Z₀₅₄₁₇, an ErbB3-binding Affibody molecule [45], was used as positive control